Affordable Access

Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate.

Authors
  • Katakkar, S B
  • Franks, C R
Type
Published Article
Journal
Cancer treatment reports
Publication Date
Sep 01, 1978
Volume
62
Issue
9
Pages
1379–1380
Identifiers
PMID: 688282
Source
Medline
License
Unknown

Abstract

In a phase II study, eight patients with metastatic renal cell carcinoma have been treated with a combination of chemotherapy and hormonal therapy using adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate. Five patients have responded, including one with complete response, one with subjective improvement, and three with partial responses. The median survival was 4 months with a range of 4--11 months. With the exception of mild alopecia and nausea, toxicity was minimal; no significant hematologic toxicity was noted. The initial results of this study suggest that chemo-hormonal therapy plays a significant role in the management of renal cell carcinoma.

Report this publication

Statistics

Seen <100 times